News
U.S. approves first-ever biannual shot to prevent HIV, but getting it might be hard
WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.S. and abroad will get access to the powerful new option.
6 things to know about lenacapavir, what experts call a ‘wonder drug’ for preventing HIV
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts say lenacapavir is easier to administer, and each dose lasts longer compared to other medications.
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...
Asianet Newsable on MSN2d
Groundbreaking HIV supercharged vaccine could protect well with just one doseResearchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...
On May 30, a team of researchers funded by the National Institutes of Health got the word: Funding for their vaccine ...
According to a phase 1 trial, the experimental HIVconsvX vaccine is safe and immunogenic among sub-Saharan African ...
The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...
The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.
HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...
The US Food and Drug Administration (FDA) has approved use of the vaccine Yeztugo, manufactured by Gilead Sciences, is an anti-HIV drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback